J1412 Valoctocogene Roxaparvovec | HCPCS Reimbursement

HCPCS Level II code J1412 identifies an injectable formulation of valoctocogene roxaparvovec-rvox, a gene therapy product specified per milliliter with a nominal 2 x 10^13 vector genomes. As an HCPCS Level II biologic code for a high-cost, specialty gene therapy, it matters nationally for payer coverage policies, prior authorization workflows, and site-of-service planning given the complexity and cost of administration.

Key payers in the national discussion include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what this code represents clinically, typical settings where the product is administered, and the implications for billing and policy. The publication includes benchmarking of payer coverage approaches, common billing modifiers and claim considerations, and context on clinical use and coding relationships where available.

This summary is intended to orient clinical billing teams, revenue cycle professionals, and policy analysts to the primary coding and care-delivery considerations tied to J1412, and to highlight areas where payer policy and administration processes are commonly applied. Data not available in the input is noted where relevant in detailed sections.

Billing Code Overview

HCPCS Level II code J1412 describes an injection of valoctocogene roxaparvovec-rvox per milliliter, containing nominal 2 x 10^13 vector genomes. This entry represents a gene therapy product supplied for intravenous or intramuscular administration as an injectable biologic.

Service type: Gene therapy injection administered as a one-time or limited series biologic treatment intended to deliver a viral vector carrying therapeutic genetic material.

Typical site of service: Hospital outpatient infusion center, specialty infusion clinic, or ambulatory surgical center equipped to handle advanced biologic and gene therapy administration.

Clinical Context

A 32-year-old male with severe hemophilia A and inhibitors is evaluated in a tertiary care hematology clinic for gene therapy. After multidisciplinary assessment including baseline factor VIII activity, inhibitor titers, liver function tests, and vector suitability, the patient is scheduled for administration of valoctocogene roxaparvovec (J1412) delivered as a single intravenous infusion containing the specified vector genomes. Typical workflow: pre-infusion evaluation (consent, labs, immunologic screening), inpatient or outpatient infusion under monitored conditions (infusion suite or hospital outpatient infusion center), post-infusion observation (monitoring for infusion reactions, liver enzyme surveillance), and scheduled follow-up visits for efficacy and safety labs. The typical site of service is an outpatient infusion center or hospital outpatient department; complex cases may use inpatient admission for monitoring. Patient scenario includes prior documented severe congenital hemophilia A (factor VIII deficiency), prior factor replacement history, and counseling regarding potential risks such as transaminase elevations, immune responses, and need for long-term monitoring of factor VIII activity and inhibitor development.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier (standard)	Use when no special circumstances apply to the administration of the drug.

Taxonomy Code	Specialty	Notes
`2080P0207X`	Hematology & Oncology	Hematologists oversee patient selection, dosing decisions, and longitudinal follow-up for gene therapy.
`208000000X`	Hematology	Specialists in bleeding disorders who manage peri-infusion care and inhibitor surveillance.
`363L00000X`	Infusion Therapy	Infusion nurses and specialists who administer the product and monitor for immediate reactions.
`207P00000X`	Medical Oncology	May be involved in gene therapy programs and institutional oversight.
`3336C0003X`	Transfusion Medicine	Laboratory and transfusion medicine specialists involved in monitoring factor levels and compatibility when needed.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D66`	Hereditary factor VIII deficiency (Hemophilia A)	Primary indication for valoctocogene roxaparvovec gene therapy to increase endogenous factor VIII activity.
`D68.4`	Acquired coagulation factor deficiency	Relevant if differential diagnosis or coexisting coagulation disorder must be considered prior to gene therapy.
`Z79.01`	Long-term (current) use of anticoagulants	Important to document as anticoagulant therapy may affect bleeding risk and management around infusion.
`Z51.11`	Encounter for antineoplastic chemotherapy	Used in institutional coding workflows for gene therapy administrations that follow chemotherapy/biologic infusion encounter conventions.
`R79.89`	Other abnormal findings of blood chemistry	Used for abnormal baseline or post-infusion laboratory values such as elevated transaminases requiring monitoring.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Commonly billed for the initial period of an IV infusion when documenting infusion time for administration of a complex biologic agent.
`96366`	Intravenous infusion, each additional hour	Billed when the infusion or monitored administration extends beyond the initial hour.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Used if adjunctive injections (e.g., corticosteroid for reaction) are given during the course of care; not for the primary IV gene therapy product.
`36415`	Collection of venous blood by venipuncture	Billed for blood draws required for baseline testing and post-infusion monitoring (liver enzymes, factor VIII activity, inhibitor titers).
`96374`	Therapeutic, prophylactic, or diagnostic IV push, each additional substance/drug	Used for IV push medications administered in the course of infusion-related management (e.g., antiemetics, rescue meds).

OpenPayer

Summary & Overview

HCPCS J1412: Valoctocogene Roxaparvovec Gene Therapy Injection